Download full-text PDF

Source

Publication Analysis

Top Keywords

[radiobiological alpha-emitting
4
alpha-emitting radionuclides
4
radionuclides incorporated
4
incorporated lungs
4
lungs microdistribution
4
microdistribution lungs
4
lungs insoluble
4
insoluble dusts
4
dusts thorium-232]
4
lungs
2

Similar Publications

Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review.

Pharmaceuticals (Basel)

March 2024

School of Biomedical Engineering & Imaging Sciences, King's College London, London SE1 7EP, UK.

This review article explores the evolving landscape of Molecular Radiotherapy (MRT), emphasizing Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumours (NETs). The primary focus is on the transition from β-emitting radiopharmaceuticals to α-emitting agents in PRRT, offering a critical analysis of the radiobiological basis, clinical applications, and ongoing developments in Targeted Alpha Therapy (TAT). Through an extensive literature review, the article delves into the mechanisms and effectiveness of PRRT in targeting somatostatin subtype 2 receptors, highlighting both its successes and limitations.

View Article and Find Full Text PDF

Targeted Alpha Therapy: Current Clinical Applications.

Cancer Biother Radiopharm

August 2020

The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom.

α-Emitting radionuclides have been approved for cancer treatment since 2013, with increasing degrees of success. Despite this clinical utility, little is known regarding the mechanisms of action of α particles in this setting, and accurate assessments of the dosimetry underpinning their effectiveness are lacking. However, targeted alpha therapy (TAT) is gaining more attention as new targets, synthetic chemistry approaches, and α particle emitters are identified, constructed, developed, and realized.

View Article and Find Full Text PDF

At the tissue level, energy deposition in cells is determined by the microdistribution of alpha-emitting radionuclides in relation to sensitive target cells. Furthermore, the highly localized energy deposition of alpha particle tracks and the limited range of alpha particles in tissue produce a highly inhomogeneous energy deposition in traversed cell nuclei. Thus, energy deposition in cell nuclei in a given tissue is characterized by the probability of alpha particle hits and, in the case of a hit, by the energy deposited there.

View Article and Find Full Text PDF

Targeted Radionuclide Therapy: A Historical and Personal Review.

Semin Nucl Med

January 2020

New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY. Electronic address:

This review traces the development of targeted radionuclide therapy (TRT) (the Magic Bullet) from the discovery of radioactivity in nature and the subsequent discovery of artificial radioactivity (the production of radioactive isotopes of stable elements) to the current status of TRT in the medical literature and clinical practice. With the availability of radioisotopes of iodine, initially to study thyroidal iodine kinetics, it was soon observed that sufficient amounts of radiation could control thyroid hyperfunction. Shortly thereafter, when radioiodine was administered to a patient with differentiated thyroid carcinoma whose hypermetabolism was secondary to excess thyroid hormone production, it was observed that radioiodine also had an antitumor effect.

View Article and Find Full Text PDF

The use of alpha particles irradiation in clinical practice has gained interest in the past years, for example with the advance of radionuclide therapy. The lack of affordable and easily accessible irradiation systems to study the cell biological impact of alpha particles hampers broad investigation. Here we present a novel alpha particle irradiation set-up for uniform irradiation of cell cultures.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!